Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study
Anlotinib combined with envafolimab demonstrates promising efficacy and manageable safety in treating unresectable or metastatic liposarcoma.
Authors
- Fabo Qiu
- Hongliang Liu (ORCID: https://orcid.org/0000-0001-5880-3904)
- Bin Zhou (ORCID: https://orcid.org/0000-0002-8578-8655)
- Mengxing Cheng
- Qisheng Hao
- Xi Wang (ORCID: https://orcid.org/0009-0009-5146-8408)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Women and Children's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fonc.2024.1502945
- Citations
- 1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52